Middle East and Africa Gene Synthesis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Middle East and Africa Gene Synthesis Market Overview

The Middle East and Africa gene synthesis market was valued at USD 86.49 million in 2025 and is projected to reach USD 312.11 million by 2033, growing at a CAGR of 17.40% from 2026 to 2033. The market is witnessing steady expansion driven by increasing adoption of synthetic biology applications, rising investments in genomic research infrastructure, and growing demand for advanced molecular biology tools in healthcare, agriculture, and biotechnology sectors.

The growing prevalence of genetic disorders and infectious diseases across several MEA countries, along with increasing focus on precision medicine and vaccine development, is accelerating the demand for gene synthesis services. In addition, expanding government and private sector initiatives to strengthen biotechnology capabilities, coupled with rising collaborations with global life sciences companies and research institutions, are further supporting market growth. The gradual integration of automation and AI-enabled gene design platforms is also improving synthesis speed, accuracy, and cost efficiency, enabling broader adoption across academic and commercial end-users.

Key Market Trends & Insights

• Saudi Arabia dominated the Middle East and Africa gene synthesis market with the largest revenue share of 21.6% in 2025, supported by strong government-led genomics initiatives, expanding biotech infrastructure, and rising investment in precision medicine programs.
• The Consumables segment led the market with a 46.2% share in 2025, driven by continuous and recurring demand for nucleotides, enzymes, and reagents used in gene construction workflows.
• The United Arab Emirates is expected to be the fastest-growing country at a CAGR of 11.4% from 2026 to 2033, fueled by rapid expansion of biotechnology clusters, strong healthcare innovation funding, and adoption of advanced synthetic biology platforms.
• Software & Services are the fastest-growing component type, projected to register a CAGR of 10.9%, reflecting the surge in use of AI-based gene design platforms and cloud-based bioinformatics tools.
• The Standard Gene segment dominated the gene type category with a 52.5% revenue share in 2025, led by widespread use in basic research, cloning, and routine genetic engineering applications.
• Custom Gene Synthesis accounted for 61.8% of the market, preferred by strong demand for tailored DNA sequences in pharmaceutical research, vaccine development, and genetic engineering.
• The Vaccine Design segment is the fastest-growing application category, with a CAGR of 11.5%, driven by the increasing focus on infectious disease prevention and pandemic preparedness.

Market Size & Forecast

• Global Market Value (2025): USD 86.49 Million
• Expected Market Value (2033): USD 312.11 Million
• Forecast CAGR (2026–2033): 17.40%
• Leading Country in 2025: Saudi Arabia
• Fastest Growing Country: United Arab Emirates

Report Scope and Middle East and Africa Gene Synthesis Market Segmentation

Middle East and Africa Gene Synthesis Market Trends

Trend: Expansion of National Genomics & Precision Medicine Programs

Government-backed genomic initiatives are increasingly shaping gene synthesis demand across Middle East and Africa, with countries investing in population-scale sequencing, rare disease mapping, and precision healthcare frameworks. Academic and research institutions are adopting synthetic DNA technologies for disease modeling and vaccine research, while biotechnology parks and innovation hubs are accelerating translational research. Integration of high-throughput synthesis platforms and cloud-based bioinformatics is improving research speed and collaboration across borders. for instance, Saudi Arabia’s Saudi Human Genome Program and South Africa’s SAMRC genomics initiatives are expanding large-scale genomic data generation and synthesis adoption.

Middle East and Africa Gene Synthesis Market Dynamics

Key Market Driver: Rising Demand for Genomic Research & Biopharmaceutical Innovation

The increasing burden of genetic disorders, infectious diseases, and emerging health challenges is driving strong demand for gene synthesis in drug discovery, diagnostics, and therapeutic development across Middle East and Africa. Pharmaceutical companies, research institutes, and government health agencies are investing in synthetic biology tools to accelerate vaccine development and precision medicine applications. Expanding collaborations with global biotech firms are further strengthening technology transfer and infrastructure development. for instance, UAE-based biotech research centers and South Africa’s leading universities are expanding synthetic biology pipelines for therapeutic innovation.

Key Restraint/Challenge: High Cost and Limited Infrastructure Availability

A major restraint in the Middle East and Africa gene synthesis market is the high cost of advanced synthesis platforms combined with limited access to specialized infrastructure in several developing economies. Many research institutions and biotech startups face challenges in acquiring automated gene synthesis systems and maintaining required bioinformatics capabilities. Dependence on imported reagents and limited skilled workforce further increases operational complexity and cost barriers. for instance, smaller laboratories in Kenya and Egypt often rely on external gene synthesis service providers due to lack of in-house high-throughput synthesis capabilities.

Key Market Opportunity: Expansion of Biotech Clusters and AI-Driven Gene Design Platforms

The integration of AI-enabled gene design tools and the rapid development of biotechnology clusters present significant growth opportunities across Middle East and Africa. Cloud-based synthesis platforms and automated design software are enabling faster, more accurate DNA construction and supporting collaborative research between academic and commercial organizations. Governments are actively promoting biotech innovation zones to attract foreign investment and strengthen domestic capabilities. for instance, Saudi Arabia’s NEOM biotech initiatives and South Africa’s innovation hubs are fostering AI-driven genomic research and synthetic biology commercialization.

Middle East and Africa Gene Synthesis Market Scope

The Middle East and Africa gene synthesis market is segmented on the basis of component, gene type, gene synthesis type, application, method, end user, and distribution channel.

• By Component

On the basis of component, the Middle East and Africa gene synthesis market is segmented into synthesizer, consumables, and software & services. The Consumables segment dominated the market with an estimated 46.2% share in 2025, driven by continuous and recurring demand for nucleotides, enzymes, and reagents used in gene construction workflows. Consumables are essential across all synthesis platforms, ensuring steady revenue generation for suppliers. Increasing genomic research activities and expanding diagnostic applications are further strengthening demand. Academic and pharmaceutical laboratories rely heavily on consumables for daily operations, supporting sustained market dominance. Rising adoption of automated synthesis systems is also increasing consumable utilization rates. However, price sensitivity in emerging economies slightly limits high-end consumable adoption.

The Software & Services segment is expected to witness the fastest growth at a CAGR of 10.9% from 2026 to 2033, driven by increasing use of AI-based gene design platforms and cloud-based bioinformatics tools. These solutions enable faster gene sequence optimization and improved accuracy in synthetic biology workflows. Growing demand for outsourcing gene synthesis services among small laboratories is also supporting expansion. Integration of machine learning algorithms for error reduction and sequence prediction is enhancing efficiency. Rising collaborations between biotech firms and software providers are further accelerating adoption. Increasing digitalization of life sciences research is making software platforms a critical growth driver.

• By Gene Type

On the basis of gene type, the market is segmented into standard gene, express gene, complex gene, and others. The Standard Gene segment dominated the market with an estimated 52.5% share in 2025, supported by widespread use in basic research, cloning, and routine genetic engineering applications. Standard genes are easier and faster to synthesize, making them highly preferred in academic and diagnostic laboratories. Their lower cost compared to complex constructs further drives adoption across emerging markets. Continuous demand in pharmaceutical R&D and molecular biology studies reinforces segment dominance. Availability of standardized synthesis protocols also enhances scalability. However, limited application in advanced therapeutic research slightly restricts growth potential.

The Complex Gene segment is expected to register the fastest growth at a CAGR of 11.3% from 2026 to 2033, driven by rising demand for multi-domain genes, synthetic constructs, and engineered sequences used in advanced therapeutics. Increasing focus on gene therapy, CRISPR-based editing, and vaccine development is fueling demand. These genes require high-precision synthesis technologies, pushing innovation in enzyme-based and AI-driven platforms. Growing investments in personalized medicine are further accelerating adoption. Expansion of biotechnology research hubs across Saudi Arabia and South Africa is supporting complex gene production. Rising demand for customized genetic constructs is making this segment highly lucrative.

• By Gene Synthesis Type

On the basis of gene synthesis type, the market is segmented into gene library synthesis and custom gene synthesis. The Custom Gene Synthesis segment dominated the market with an estimated 61.8% share in 2025, driven by strong demand for tailored DNA sequences in pharmaceutical research, vaccine development, and genetic engineering. Researchers prefer custom synthesis for high precision and application-specific requirements. Increasing adoption in CRISPR research and synthetic biology is further strengthening demand. Pharmaceutical companies rely heavily on customized constructs for drug discovery pipelines. Advancements in automation have improved turnaround time and accuracy. However, higher cost compared to standard library synthesis remains a limiting factor.

The Gene Library Synthesis segment is expected to witness the fastest growth at a CAGR of 10.6% from 2026 to 2033, driven by increasing demand for large-scale genomic screening and functional genomics studies. Gene libraries enable high-throughput experimentation, accelerating discovery processes. Expanding use in antibody screening and protein engineering is further boosting adoption. Rising investments in AI-driven drug discovery platforms are supporting growth. Academic institutions are increasingly using gene libraries for research efficiency. The segment benefits from cost-sharing models and scalability advantages.

• By Application

On the basis of application, the market is segmented into synthetic biology, genetic engineering, vaccine design, therapeutic antibodies, and others. The Synthetic Biology segment dominated the market with an estimated 34.7% share in 2025, driven by strong adoption in metabolic engineering, industrial biotechnology, and microbial strain development. Synthetic biology enables creation of novel biological systems for healthcare and agriculture applications. Increasing government funding and private investment in biotech innovation is strengthening demand. Expanding research collaborations with global life science companies are further supporting growth. Academic institutions are actively adopting synthetic biology tools for experimental research. However, regulatory complexity in some countries slightly slows commercialization.

The Vaccine Design segment is expected to witness the fastest growth at a CAGR of 11.5% from 2026 to 2033, driven by increasing focus on infectious disease prevention and pandemic preparedness. Gene synthesis plays a critical role in rapid antigen design and vaccine prototyping. Rising investments in mRNA vaccine research and development are accelerating adoption. Governments are strengthening biotechnology infrastructure for emergency response capabilities. Collaboration between public health agencies and biotech firms is further boosting innovation. Expanding clinical trials across Saudi Arabia and South Africa are supporting rapid growth.

• By Method

On the basis of method, the market is segmented into solid phase synthesis, chip-based DNA synthesis, and PCR-based enzyme synthesis. The Solid Phase Synthesis segment dominated the market with an estimated 49.3% share in 2025, driven by its established reliability, scalability, and widespread use in commercial gene production. It allows controlled stepwise assembly of DNA sequences with high accuracy. Academic and pharmaceutical laboratories prefer this method due to standardized protocols. Strong presence of existing infrastructure across research institutions supports dominance. Continuous improvements in automation are enhancing throughput. However, relatively longer synthesis time compared to enzymatic methods limits efficiency.

The PCR-Based Enzyme Synthesis segment is expected to witness the fastest growth at a CAGR of 11.1% from 2026 to 2033, driven by demand for faster and more cost-effective DNA assembly methods. This technique enables high-speed amplification and assembly of gene fragments. Increasing adoption in synthetic biology and CRISPR research is accelerating demand. Lower reagent requirements make it suitable for cost-sensitive markets in Africa. Technological advancements are improving accuracy and reducing error rates. Expanding use in vaccine development and diagnostics is further supporting growth.

• By End User

On the basis of end user, the market is segmented into academic & research institutes, diagnostics laboratories, biotech & pharmaceutical companies, and others. The Biotech & Pharmaceutical Companies segment dominated the market with an estimated 44.6% share in 2025, driven by strong investments in drug discovery, gene therapy, and vaccine development. These organizations rely heavily on gene synthesis for pipeline acceleration and innovation. Increasing adoption of precision medicine is further strengthening demand. Strategic partnerships with global biotech firms are enhancing technological capabilities. Large R&D budgets enable adoption of advanced synthesis platforms. However, high operational costs remain a consideration in smaller firms.

The Academic & Research Institutes segment is expected to witness the fastest growth at a CAGR of 10.7% from 2026 to 2033, driven by expanding genomic research programs and government funding initiatives. Universities are increasingly using gene synthesis for molecular biology and synthetic biology studies. Rising collaborations with international research organizations are boosting capability development. Growth in biotechnology education programs is expanding user base. Increasing availability of grant funding is supporting experimental research. The segment benefits from strong focus on innovation and early-stage discovery.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, online distribution, and third-party distribution. The Direct Tender segment dominated the market with an estimated 57.4% share in 2025, driven by large-scale procurement by government institutions, research organizations, and pharmaceutical companies. Direct procurement ensures quality assurance and regulatory compliance. Long-term supply contracts with biotech suppliers further strengthen this channel. Bulk purchasing for national genomics projects supports dominance. Established supplier relationships enhance reliability and consistency. However, procurement cycles can be lengthy and complex.

The Online Distribution segment is expected to witness the fastest growth at a CAGR of 12.0% from 2026 to 2033, driven by increasing digitalization of biotech procurement and rising demand for fast, flexible ordering systems. Online platforms enable easier access to gene synthesis services for small laboratories. Integration of AI-based ordering and sequence optimization tools is enhancing efficiency. Growing adoption of cloud-based biotech marketplaces is further supporting expansion. Cost transparency and faster turnaround times are attracting new users. Increasing internet penetration across Middle East and Africa is accelerating this shift.

Middle East and Africa Gene Synthesis Market Regional Analysis

Saudi Arabia dominated the Middle East and Africa gene synthesis market with the largest revenue share of 21.6% in 2025, supported by strong government-led genomics initiatives, expanding biotech infrastructure, and rising investment in precision medicine programs. The country is actively strengthening its life sciences ecosystem through dedicated biotech hubs, research funding, and collaborations with global pharmaceutical and synthetic biology companies. Increasing adoption of gene synthesis in drug discovery, vaccine development, and rare disease research is further accelerating market growth. Rising focus on advanced healthcare transformation under national strategic programs continues to reinforce Saudi Arabia’s leadership position in the regional market.

The Saudi Arabia Gene Synthesis Market Insight

The Saudi Arabia gene synthesis market is witnessing strong growth due to increasing government investment in genomics programs, expanding biotechnology infrastructure, and rising focus on precision medicine and rare disease research. Large-scale initiatives such as national genome sequencing projects and biotech cluster development are driving demand for advanced gene synthesis technologies. Growing adoption of synthetic biology in drug discovery, vaccine development, and molecular diagnostics is further supporting market expansion. In addition, collaborations with global life science companies and rising R&D funding are strengthening the country’s position as the leading market in the Middle East and Africa region.

United Arab Emirates Gene Synthesis Market Insight

The United Arab Emirates gene synthesis market is experiencing rapid growth, driven by strong investments in biotechnology innovation hubs, advanced healthcare infrastructure, and increasing focus on AI-enabled life sciences research. Government initiatives promoting precision medicine and genomic medicine adoption are significantly boosting demand for gene synthesis services. Expanding partnerships with international biotech firms and research organizations are accelerating technology transfer and capability building. Moreover, rising applications in synthetic biology, vaccine design, and personalized medicine are positioning the UAE as one of the fastest-growing markets in the region.

South Africa Gene Synthesis Market Insight

The South Africa gene synthesis market is steadily expanding, supported by growing genomic research activities, increasing prevalence of genetic disorders, and strong academic research capabilities. Universities and research institutions are actively engaging in synthetic biology and molecular genetics studies, driving demand for gene synthesis tools and services. Government and private sector collaborations aimed at strengthening biotechnology infrastructure are further supporting market development. In addition, rising focus on infectious disease research, vaccine development, and agricultural biotechnology applications is enhancing market growth across the country.

Egypt Gene Synthesis Market Insight

The Egypt gene synthesis market is growing gradually due to increasing investments in healthcare research, expanding biotechnology education programs, and rising focus on improving diagnostic capabilities. Academic institutions and research laboratories are adopting gene synthesis technologies for genetic studies and molecular biology applications. Government efforts to strengthen healthcare infrastructure and support scientific innovation are further contributing to market development. However, limited access to advanced synthesis platforms and high operational costs continue to restrain large-scale adoption, despite growing interest in synthetic biology applications.

Middle East and Africa Gene Synthesis Market Share

The Middle East and Africa Gene Synthesis industry is primarily led by well-established companies, including:

• GenScript Biotech Corporation (China)
• BGI Genomics Co., Ltd. (China)
• WuXi Biologics Inc. (China)
• Thermo Fisher Scientific, Inc. (U.S.)
• Takara Bio Inc. (Japan)
• Sysmex Corporation (Japan)
• Fujifilm Diosynth Biotechnologies (Japan)
• Nippon Gene Co., Ltd. (Japan)
• Synbio Technologies (China)
• Sangon Biotech Co., Ltd. (China)
• Shanghai GeneChem Co., Ltd. (China)
• Origene Technologies (U.S.)
• Integrated DNA Technologies (U.S.)
• Eurofins Genomics (Luxembourg)
• Bioneer Corporation (South Korea)
• Macrogen Inc. (South Korea)
• Cosmo Bio Co., Ltd. (Japan)
• Novogene Co., Ltd. (China)
• Azenta Life Sciences (U.S.)
• WuXi AppTec Co., Ltd. (China)

Latest Developments in Middle East and Africa Gene Synthesis Market

• In March 2025, the United Arab Emirates-based healthcare and life sciences ecosystem expanded its genomics capabilities through enhanced integration of advanced gene sequencing and synthesis technologies under national precision medicine programs. The initiative focuses on strengthening genomic databases and accelerating synthetic biology applications for rare disease diagnosis and personalized treatment development. The development reflects the country’s broader strategy to position itself as a regional biotechnology hub, supported by international research collaborations and AI-enabled bioinformatics platforms. It also enhances translational research capabilities across hospitals and academic institutions in the region
• In September 2024, Saudi Arabia advanced its national genomics agenda through continued expansion of population-scale genome sequencing initiatives aimed at improving disease prevention and precision healthcare delivery. The program supports the use of synthetic gene technologies in biomedical research, vaccine development, and genetic disorder analysis. It is backed by strong government funding and partnerships with global life sciences companies to strengthen domestic biotechnology capacity. This initiative further reinforces Saudi Arabia’s leadership role in the Middle East and Africa gene synthesis ecosystem
• In June 2023, South Africa strengthened its molecular biology and synthetic biology research landscape through expanded funding for genomic science programs under national medical research frameworks. The initiative supports academic institutions and biotech research centers in adopting gene synthesis tools for infectious disease studies and agricultural biotechnology applications. It also promotes collaboration with international research organizations to enhance local scientific capabilities. This development is contributing to the gradual expansion of gene synthesis adoption in the African biotechnology sector
• In November 2022, Israel’s biotechnology ecosystem saw increased activity in synthetic biology and gene engineering research driven by startup innovation and academic–industry collaboration. Companies and research institutes expanded the use of gene synthesis technologies for drug discovery, CRISPR-based applications, and personalized medicine development. Strong venture capital funding and government-backed innovation programs further supported advancements in genomic engineering. This reinforced Israel’s position as one of the most advanced biotechnology hubs in the Middle East region
• In February 2021, Qatar continued strengthening its national genomics program by expanding research initiatives focused on population health studies and genetic disease mapping. The program incorporates advanced gene sequencing and synthesis technologies to support precision medicine and biomedical research. Collaboration with international research institutions and healthcare organizations has enabled improved access to synthetic biology tools. This initiative plays a key role in enhancing regional genomic research capabilities and supporting long-term healthcare innovation

SKU-62812